pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Small Molecule · news · pharmadog
← back to Small Molecule
News · Small Molecule
292
stories
9d
Building Resilience for the Future of Biopharma Innovation
fiercebiotech
9d
After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’
biospace
9d
AbCellera’s menopause medicine ‘sets new efficacy bar’ for hot flashes
biospace
9d
Vaderis fuels up with $152M series B to test rare vascular disease in Phase 3
biospace
9d
Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug
fiercebiotech
10d
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
biospace
10d
All eyes on psychedelic drugmakers as Definium, Compass near major catalysts
biospace
10d
‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder
fiercebiotech
10d
STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study
stat
10d
Opinion: We prepared for Ebola — but not this Ebola
stat
10d
Opinion: We prepared for Ebola — but not this Ebola
stat
10d
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
fiercebiotech
10d
Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
fiercebiotech
10d
Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program
fiercebiotech
10d
aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug
fiercebiotech
10d
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
biospace
10d
Psychedelics on the cusp of market breakthrough as clinical, policy support grow
biospace
13d
Is the biotech capital of the world moving?
stat
13d
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
13d
Novo Nordisk’s CFO on the oral Wegovy rollout and beyond
fiercebiotech
14d
BioVie shares halve on murky Parkinson’s disease readout
biospace
14d
Chutes & Ladders—BioNTech brings in Sobi CEO
fiercebiotech
14d
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
14d
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
biospace
14d
Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug
fiercebiotech
14d
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
fiercebiotech
15d
FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms
fda press
15d
Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
biospace
15d
STAT+: Could poop pills be the next treatment for food allergies?
stat
15d
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
biospace
← prev
page 2 of 10
next →
